Patents Assigned to CXL Ophthalmics, LLC
  • Patent number: 12156834
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: December 3, 2024
    Assignee: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A Hartman
  • Patent number: 11497766
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: November 15, 2022
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 11135090
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: October 5, 2021
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
  • Patent number: 11033429
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 15, 2021
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
  • Patent number: 10729716
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: August 4, 2020
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 10575986
    Abstract: A first sponge device for use to manipulate and prepare the surface of the epithelium of an eye prior to application of an ophthalmic solution has a handle and a sponge head secured to the handle. The head is made of an absorbent, wicking sponge material and has a non-sharp, tissue preparation surface of predetermined shape for rubbing across the surface of the epithelium layer in order to manipulate the tissue. After the surface is prepared, a second, holding sponge is placed over the eye to act as a reservoir and to hold ophthalmic solution against the eye surface.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: March 3, 2020
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Wayne Korteweg
  • Patent number: 10285857
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: May 14, 2019
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
  • Patent number: 10092594
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: October 9, 2018
    Assignee: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 9622911
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 18, 2017
    Assignee: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
  • Patent number: 9566301
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%), or more specifically between about 0.015% to about 5%, sodium iodine or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: February 14, 2017
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 9555111
    Abstract: Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 31, 2017
    Assignee: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Publication number: 20150126921
    Abstract: Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.
    Type: Application
    Filed: March 27, 2013
    Publication date: May 7, 2015
    Applicant: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Publication number: 20150088231
    Abstract: Systems and methods of ophthalmologic or ocular phototherapy treatment are provided herein. In some embodiments, the systems and methods of ophthalmic or ocular phototherapy treatment comprise applying a treatment light beam in a predetermined wavelength or wavelength range corresponding to gold (yellow to orange), red, or at least part of both the gold and red visible light wavelength ranges to at least a portion of an eye. The treatment light beam may be applied to an entire eye. In some embodiments, the selected treatment area is irradiated with light in the selected gold and/or red wavelength range at a predetermined dose for a selected time period as a primary treatment in order to treat various eye conditions and reduce eye pain or discomfort, or help to promote eye wound healing following injury or surgery, or as a secondary treatment to augment eye treatment using light in different phototherapy treatment ranges.
    Type: Application
    Filed: March 26, 2013
    Publication date: March 26, 2015
    Applicant: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Publication number: 20140249509
    Abstract: A first sponge device for use to manipulate and prepare the surface of the epithelium of an eye prior to application of an ophthalmic solution has a handle and a sponge head secured to the handle. The head is made of an absorbent, wicking sponge material and has a non-sharp, tissue preparation surface of predetermined shape for rubbing across the surface of the epithelium layer in order to manipulate the tissue. After the surface is prepared, a second, holding sponge is placed over the eye to act as a reservoir and to hold ophthalmic solution against the eye surface.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicant: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Wayne Korteweg
  • Publication number: 20140194957
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Application
    Filed: March 12, 2014
    Publication date: July 10, 2014
    Applicant: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman